Pejawar seer confers ‘Rashtra Ratna Prashasti’ on Narayana Murthy

Kasaragod, Mar 31: The latest incidents of critically-ill patients dying due to lack of medical attention has been a cause of concern for the people here who had largely been depended on hospitals in Mangalore.

However the lock down has hindered follow-up treatment for these critically ill as the Karnataka authorities has been steadfast in restricting entry into their land.

The people of Kasaragod has been largely depended on the medical facilities in Mangalore for critical illness care. It was the gross inadequacies in critical healthcare in the district besides rather-easy proximity to nearby and bigger town that many residing on the north-east of the district have since long been making it to Mangalore for treatment of critical illness like cancer, dialysis and the alike.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Bengaluru, Jan 16: It was necessary to revise rates under the ECHS, CGHS and GIPSA schemes for private hospitals to be able to sustain, doctors from private hospitals have opined.

Under the banner of the Association of Healthcare Providers of India (AHPI), doctors from top private hospitals in the city spoke about the dues pending from the union government schemes. They said they could not give a deadline as to when they would stop offering the scheme.

In a press release issued here on Thursday association said, which had previously told the government that they would not treat patients under the scheme owing to dues, mellowed down after the government released Rs 250 crore out of the Rs 1,000 crore dues.